Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 6:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336437
FAQ
- What is Generate Biomedicines, Inc.'s D&A?
- Generate Biomedicines, Inc. (GENB) reported D&A of $3.2M in Q2 2026.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Generate Biomedicines, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude